A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
PUMA BIOTECHNOLOGY, INC.
PBYI
$407M
Mkt Cap
$7.98
-0.37%
PUMA BIOTECHNOLOGY, INC. (PBYI) has a current P/E ratio of 13.1, compared to its historical median P/E of 9.7. The stock is currently considered Expensive based on its historical valuation range.
PUMA BIOTECHNOLOGY, INC. (PBYI) has a 5-year average return on invested capital (ROIC) of 17.9%. This indicates strong capital allocation and a potential competitive advantage.
PUMA BIOTECHNOLOGY, INC. (PBYI) has a market capitalization of $407M. It is classified as a small-cap stock.
PUMA BIOTECHNOLOGY, INC. (PBYI) does not currently pay a regular dividend.
Based on historical P/E analysis, PUMA BIOTECHNOLOGY, INC. (PBYI) appears expensive. The current P/E of 13.1 is 35% above its historical median of 9.7. The estimated fair value CAGR (P/E method) is 73.0%.
PUMA BIOTECHNOLOGY, INC. (PBYI) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PUMA BIOTECHNOLOGY, INC. (PBYI) reported annual revenue of $228 million in its most recent fiscal year, based on SEC EDGAR filings.
Company Overview Unless otherwise provided in this Annual Report, references to the “Company,” “we,” “us,” and “our” refer to Puma Biotechnology, Inc. and our wholly owned subsidiary. We are a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. Additionally, we have in-licensed, and are responsible for global development and commercialization of, alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on Aurora Kinase A.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 228M | 228M | 230M | 236M | 228M | 253M |
| Net Income | 31M | 31M | 30M | 22M | - | -29M |
| EPS | $0.61 | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 |
| Free Cash Flow | 42M | 42M | 39M | 27M | -16M | 21M |
| ROIC | 24.5% | 39.5% | 28.8% | 34.1% | - | -30.8% |
| Gross Margin | 74.5% | 74.5% | 72.1% | 73.4% | 75.8% | 74.8% |
| Debt/Equity | 0.35 | 0.35 | 1.22 | 2.50 | 4.55 | -39.69 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 37M | 37M | 31M | 33M | 24M | -16M |
| Operating Margin | 16.3% | 16.3% | 13.4% | 13.9% | 10.4% | -6.3% |
| ROE | 23.9% | 28.0% | 32.9% | 40.4% | - | - |
| Shares Outstanding | 51M | 51M | 49M | 48M | 48M | 40M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | N/A | 251M | 272M | 225M | 253M | 228M | 236M | 230M | 228M | 228M |
| Gross Margin | N/A | N/A | N/A | 82.5% | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% | 74.5% |
| R&D | 208M | 165M | 133M | 98M | 72M | 52M | 50M | 55M | 62M | 62M |
| SG&A | 107M | 146M | 142M | 118M | 116M | 90M | 90M | 80M | 71M | 71M |
| EBIT | -292M | -95M | -39M | -30M | -16M | 24M | 33M | 31M | 37M | 37M |
| Op. Margin | N/A | -37.7% | -14.3% | -13.5% | -6.3% | 10.4% | 13.9% | 13.4% | 16.3% | 16.3% |
| Net Income | -292M | -114M | -76M | -60M | -29M | N/A | 22M | 30M | 31M | 31M |
| Net Margin | N/A | -45.3% | -27.8% | -26.7% | -11.5% | N/A | 9.2% | 13.1% | 13.6% | 13.6% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||||
| ROIC | -139.5% | -61.0% | -67.2% | -76.8% | -30.8% | N/A | 34.1% | 28.8% | 39.5% | 24.5% |
| ROE | -547.7% | -331.1% | -432.9% | N/A | N/A | N/A | 40.4% | 32.9% | 28.0% | 23.9% |
| ROA | -176.4% | -43.8% | -32.2% | -24.6% | -12.9% | N/A | 9.4% | 14.2% | 14.5% | 14.4% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -172M | -24M | 22M | 773K | 21M | -16M | 27M | 39M | 42M | 42M |
| Free Cash Flow | -173M | -25M | 22M | 727K | 21M | -16M | 27M | 39M | 42M | 42M |
| Owner Earnings | -284M | -118M | -43M | -46M | -23M | -37M | 5.2M | 19M | 24M | 24M |
| CapEx | 431K | 439K | 306K | 46K | 0 | 0 | 140K | 56K | 71K | 71K |
| Maint. CapEx | 2.8M | 7.4M | 8.1M | 10M | 11M | 9.8M | 12M | 12M | 11M | 11M |
| Growth CapEx | 0 | 0 | 0 | 0 | N/A | N/A | 0 | 0 | 0 | 0 |
| D&A | 2.8M | 7.4M | 8.1M | 10M | 11M | 9.8M | 12M | 12M | 11M | 11M |
| CapEx/OCF | N/A | N/A | 1.4% | 6.0% | N/A | N/A | 0.5% | 0.1% | 0.2% | 0.2% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 109M | 87M | 57M | 37M | 33M | 12M | 10M | 8.2M | 6.9M | 6.9M |
| Debt Repayment | 1.6M | 4.2M | 80M | 8.4M | 100M | 0 | 0 | 33M | 44M | 44M |
| Balance Sheet | ||||||||||
| Net Debt | -115M | -14M | -17M | 19M | 15M | 17M | 38M | 11M | -52M | 15M |
| Cash & Equiv. | 82M | 108M | 60M | 85M | 63M | 76M | 85M | 69M | 30M | 30M |
| Long-Term Debt | 48M | 152M | 95M | 84M | 97M | 98M | 66M | 22M | 0 | N/A |
| Debt/Equity | 0.91 | 4.43 | 5.44 | -18.92 | -39.69 | 4.55 | 2.50 | 1.22 | 0.35 | 0.35 |
| Interest Coverage | -406.1 | -8.6 | -2.6 | -2.2 | -1.2 | 2.0 | 2.4 | 2.5 | 5.6 | 5.6 |
| Equity | 53M | 34M | 17M | -6.0M | -2.4M | 22M | 53M | 92M | 130M | 130M |
| Total Assets | 166M | 259M | 235M | 244M | 227M | 222M | 231M | 213M | 216M | 216M |
| Total Liabilities | 112M | 225M | 217M | 250M | 229M | 200M | 177M | 121M | 86M | 86M |
| Intangibles | 48M | 44M | 40M | 74M | 66M | 71M | 61M | 51M | 41M | 41M |
| Retained Earnings | -1.1B | -1.2B | -1.3B | -1.3B | -1.4B | -1.4B | -1.3B | -1.3B | -1.3B | -1.3B |
| Working Capital | 48M | 136M | 75M | 32M | 30M | 57M | 57M | 52M | 81M | 81M |
| Current Assets | 106M | 203M | 166M | 146M | 140M | 134M | 156M | 148M | 163M | 163M |
| Current Liabilities | 58M | 67M | 91M | 114M | 110M | 77M | 99M | 96M | 81M | 81M |
| Per Share Data | ||||||||||
| EPS | -7.85 | -2.99 | -1.95 | -1.52 | -0.72 | 0.00 | 0.45 | 0.62 | 0.61 | 0.61 |
| Owner EPS | -7.64 | -3.12 | -1.11 | -1.16 | -0.56 | -0.78 | 0.11 | 0.39 | 0.47 | 0.47 |
| Book Value | 1.43 | 0.90 | 0.45 | -0.15 | -0.06 | 0.45 | 1.11 | 1.89 | 2.56 | 2.56 |
| Cash Flow/Share | -4.64 | -0.63 | 0.58 | 0.02 | 0.51 | -0.33 | 0.56 | 0.80 | 0.82 | 0.82 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 37.2M | 38.0M | 38.8M | 39.5M | 40.5M | 48.2M | 48.0M | 48.8M | 51.0M | 51.0M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 9.7 | 5.0 | 10.1 | 13.1 |
| P/FCF | N/A | N/A | 15.2 | 585.8 | 6.1 | N/A | 7.8 | 3.9 | 7.5 | 9.8 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | 8.9 | 7.5 | 5.2 | 7.0 | 11.3 |
| Price/Book | 69.6 | 23.4 | 19.2 | N/A | N/A | 8.9 | 3.9 | 1.6 | 2.4 | 3.1 |
| Price/Sales | N/A | 8.0 | 2.6 | 1.8 | 1.3 | 0.6 | 0.7 | 0.8 | 0.9 | 1.8 |
| FCF Yield | -4.7% | -3.1% | 6.6% | 0.2% | 16.4% | -8.2% | 12.9% | 25.8% | 13.3% | 10.3% |
| Market Cap | 3.7B | 801M | 336M | 426M | 126M | 193M | 209M | 150M | 314M | 407M |
| Avg. Price | 73.87 | 53.11 | 18.09 | 10.08 | 8.34 | 2.86 | 3.41 | 3.92 | 3.96 | 7.98 |
| Year-End Price | 99.80 | 21.09 | 8.66 | 10.79 | 3.12 | 4.01 | 4.35 | 3.08 | 6.16 | 7.98 |
PUMA BIOTECHNOLOGY, INC. passes 5 of 9 quality checks, suggesting mixed fundamentals.
PUMA BIOTECHNOLOGY, INC. trades at 13.1x trailing earnings, compared to its 15-year median P/E of 9.7x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 9.8x vs a median of 7.5x. The company's 5-year average ROIC is 17.9% with a gross margin of 74.1%. At current prices, the estimated annualized return to fair value is +22.3%.
PUMA BIOTECHNOLOGY, INC. (PBYI) has a net profit margin of 13.6%. This is a healthy margin.
PUMA BIOTECHNOLOGY, INC. (PBYI) generated $42 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
PUMA BIOTECHNOLOGY, INC. (PBYI) has a debt-to-equity ratio of 0.35. This indicates a conservatively financed balance sheet.
PUMA BIOTECHNOLOGY, INC. (PBYI) reported earnings per share (EPS) of $0.61 in its most recent fiscal year.
PUMA BIOTECHNOLOGY, INC. (PBYI) has a return on equity (ROE) of 28.0%. This indicates the company generates strong returns for shareholders.
PUMA BIOTECHNOLOGY, INC. (PBYI) has a 5-year average gross margin of 74.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 9 years of financial data for PUMA BIOTECHNOLOGY, INC. (PBYI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PUMA BIOTECHNOLOGY, INC. (PBYI) has a book value per share of $2.56, based on its most recent annual SEC filing.